MarketPulse

retatrutide

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Lilly's Retatrutide Hits Surgery-Level Weight Loss, But IP Wars Loom

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.
PFELLYSNYNVOintellectual propertyweight loss
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Morgan Stanley Sees 52% Upside for Eli Lilly as Weight-Loss Drugs Reshape Revenue

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.
LLYCVSNVOweight loss drugsZepbound
The Motley FoolThe Motley Fool··Adria Cimino

Lilly's Retatrutide Could Cement Dominance in Surging Weight Loss Drug Market

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.
LLYNVOclinical trialsweight loss drugs
The Motley FoolThe Motley Fool··Justin Pope

Eli Lilly's FDA-Approved Obesity Pill Could Upend Novo Nordisk's Market Dominance

Eli Lilly's new GLP-1 pill Foundayo launches April 6 with fewer restrictions than competitors. Pipeline drug retatrutide shows superior weight loss, threatening Novo Nordisk's obesity market leadership.
LLYNVOFDA approvalGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly Phases Out Select European Insulin Products by 2027

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.
LLYweight lossEurope
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss